CMMS therapy for stiffness after fasciectomy for Dupuytren’s
Stiffness is a common problem after fasciectomy, particularly loss of flexion, and can be resistant to stretching exercises or splints. This therapy program, incorporating a combination of casting and active exercises, helped patients regain motion when they had failed conventional hand therapy: https://dupuytrens.org/DupPDFs/2007_Rose.pdf
NICE evaluation of needle aponeurotomy for Dupuytren’s
The source of medical information is critical; objectivity is essential. That’s one of the advantages of the UK’s NHS independent review process. Read their assessment of needle aponeurotomy:https://dupuytrens.org/DupPDFs/2004_NICE.pdf
Drugs that provoke Dupuytren’s Disease
Looking for ways to stop Dupuytren’s, it should be useful to look in reverse at factors which may start it, such as protease inhibitor drugs, as reported here: https://dupuytrens.org/DupPDFs/2002_Florence_1607.pdf
Dupuytren’s, Mast cells, Substance P
Dupuytren’s is not always painless. Sometimes, active areas itch and burn. This goes along with the finding of elevated levels of mast cells and nerve fibers containing substance P – something also found in interstitial cystitis. Find out more at https://dupuytrens.org/DupPDFs/2006_Schubert_1071.pdf
Aggressive Dupuytren’s Disease
This report of Dupuytren’s extending from the palm into the forearm reviews the anatomy of involvement and points out the aggressive nature of Dupuytren’s in young people. We need more effective biologic treatments: https://dupuytrens.org/DupPDFs/1997_Sinha_1048.pdf
Dupuytren’ s Contracture – Microscopic Analysis
This is a classic article on the biology of Dupuytren’s. Structural changes in the palmar fascia are associated with type III collagen, which isn’t normally found in this tissue. Myofibroblasts are likely the source of this and are associated with disease recurrence.Most important quote: “Clinical recurrence was not related to the age ofthe patient at […]
